References
- Brundtland GH. Challenges and opportunities of ageing in a new world. Aging Male 1998;1:229–33
- Morales A, Lunenfeld B. Androgen replacement therapy in aging men with secondary hypo- gonadism. Aging Male 2001;4:151–62
- Park JS, Hong JI, Park NC. Changes in the quality of life after transdermal testosterone (Androderm) supplement therapy in the aging male. Korean J Urol 1999;40:1057–65
- Vermeulen A, Kaufman JM. Aging of the hypothalamo–pituitary–testicular axis in men. Horm Res 1995;43:25–8
- Herbert J. The age of dehydroepiandrosterone. Lancet 1995;345:1193–4
- Bagatell CJ, Bremner WJ. Drug therapy: androgen in men. N Engl J Med 1996;334:707–14
- Ferrando AA, Sheffield-Moore M, Yeckel CW, Gilkison C, Jiang J, Achacosa A, et al. Testosterone administration to older men improves muscle function: molecular and physiological mechanism. Am J Physiol Endocrinol Metab 2002;282:E601–7
- Wiebke A, Joachim H, Frank C, Martin R, Doris H. Biotransformation of oral dehydrotestos- terone in elderly men: significant increase in circu- lating estrogens. J Clin Endocrinol Metab 1999; 84:2170–6
- Barret CE, Khaw KT, Yen SCC. A prospective study of dehydroepiandrosterone sulfate, mortality and cardiovascular disease. N Engl J Med 1986;315:1519–24
- Bartsch G, Rittmaster RS, Klocker H. Dihydro- testosterone and the concept of 5 alpha-reductase inhibition in human benign prostatic hyperplasia. Eur Urol 2000;37:367–80
- Cunningham GR. Management of male aging: which testosterone replacement therapy should be used? Aging Male 2000;3:203–9
- Charman WN, Porter CJH. Lipophilic prodrugs designed for intestinal lymphatic transport. Adv Drug Deliv Rev 1996;19:149–69
- Horst HJ, Holtjz WJ, Dennis M, Coert A, Gaelen J, Voigt KD. Lymphatic absorption and metabolism of orally administered testosterone undecanoate in man. Klin Wschr 1976;54:875–9
- Bagchus W, Hust R, Maris F, Schnabel PG, Houwing NS. Important effect of food on the bioavailability of oral testosterone undecanoeate. Pharmacotherapy 2003;23:319–25
- Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D, et al. Validation of screening questionnaire for androgen deficiency in aging males. Metabolism 2000;49:1239–42
- Howell S, Shalet S. Testosterone deficiency and replacement. Horm Res 2001;56(Suppl 1):86–92
- Bagchus WN, Schnabel PG, Maris F, Houwing NS. Effect of food on the oral bioavailability of a new Andriol formulation. J Androl 2001;(Suppl):96
- Svetek DA, Canby ED, Thomson IM, Sabenegh ES. The effect of parenteral testosterone replace- ment on prostate specific antigen in hypogonadal men with erectile dysfunction. J Urol 1997;158:1775–7
- Davidson JM, Camargo CA, Smith ER. Effect of androgen on sexual behavior in hypogonadal men. J Clin Endocrinol Metab 1979;48:955–8
- Skakkebaek NE, Bancroft J, Davidson DW, Warner P. Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study. Clin Endocrinol 1981;14:49–61
- Kwan M, Greenleaf WJ, Mann J, Crapo L, Davidson JM. The nature of androgen action on male sexuality: a combined laboratory-self-report study on hypogonadal men. J Clin Endocrinol Metab 1983;37:71–7
- Flynn V, Hellstrom WJ. Androgen deficiency in the aging male: pathophysiology, diagnosis, and treatment alternatives. Curr Urol Rep 2001;2:473–9
- Douglas TH, Connelly RR, McLeod DG, Erickson SJ, Barren R III, Murphy GP. The effect of exogenous testosterone replacement on prostate specific antigen and prostate specific membrane antigen levels in hypogonadal men. J Surg Oncol 1995;59:246–50